IMPEDIMED LIMITED — Capital/Financing Update 2014

Mar 27, 2014

==> picture [103 x 97] intentionally omitted <==

----- Start of picture text ----- ASX: IPD----- End of picture text -----

28 March 2014

ASX ANNOUNCEMENT

SUCCESSFUL A$8.8 MILLION PLACEMENT AND ANNOUNCEMENT OF SHARE PURCHASE PLAN

Brisbane, Australia - ImpediMed Limited (ASX:IPD) (“ ImpediMed ” or the “ Company ”) is pleased to announce that it has received binding commitments for a significantly oversubscribed placement of shares with domestic and international institutional investors and sophisticated investors (the “ Placement ”). The Placement, which was strongly supported by both existing and new shareholders, is for approximately 45.3 million shares at A$0.195 per share, raising approximately A$8.8 million.

The Placement price of A$0.195 per share represents an 11.4% discount to ImpediMed’s closing share price on 25 March 2014 and a 13.5% discount to the five day VWAP to 25 March 2014.

Canaccord Genuity (Australia) Limited acted as the sole Lead Manager and Bookrunner to the Placement.

ImpediMed is also pleased to announce that, following the issue of shares under the Placement, ImpediMed will offer each eligible shareholder the opportunity to subscribe for up to A$15,000 in ImpediMed shares under a Share Purchase Plan (“ SPP ”) at the same price of A$0.195 per share offered under the Placement to raise up to A$3.0 million. If ImpediMed receives valid applications exceeding A$3.0 million under the SPP, ImpediMed intends to scale back applications. Further details about the SPP are set out below.

Proceeds from the Placement and SPP will primarily be used for sales and marketing activities in the US leading up to, and following, the expected publication of a CPT[®] Category I reimbursement code (1 January 2015) for the Company’s L-Dex[®] system. The Company also intends to use the proceeds towards sponsoring post-clearance clinical trials (including trials previously announced), new product development and general working capital.

“We are very pleased with the strong support from both existing and new shareholders for this Placement which we see as a strong endorsement of the numerous achievements of the Company over the past 18 months. We are particularly excited to have the opportunity to now accelerate the sales and marketing of our L-Dex system in the US lymphoedema market following the recent acceptance of the CPT Category I code submission by the American Medical Association,” said ImpediMed President and CEO Richard Carreon.

SPP details

Participation in the SPP is open to all holders of ImpediMed shares with a registered address in Australia or New Zealand as at 7.00 pm (Sydney time) on 27 March 2014 (“ Eligible Shareholders ”).

Applicants under the SPP will not incur brokerage or other transaction costs.

All new shares issued under the SPP will rank equally with existing ImpediMed shares.

Full details of the SPP will be set out in the documentation to be sent to Eligible Shareholders shortly.

The SPP is not underwritten.

Indicative Timetable

Key dates for the Placement and SPP are set out below. The dates are indicative only and ImpediMed reserves the right to vary them, subject to the Corporations Act 2001 (Cth) and the ASX Listing Rules.

SPP Record Date (7.00 pm Sydney time)	27 March 2014
Announcement of the Placement and SPP and lifting of the tradinghalt	28 March 2014
Issue of shares under the Placement	4 April 2014
Expected date for commencement of trading of Placement shares	4 April 2014
SPP documentation posted to Eligible Shareholders and SPP offeropens	4 April 2014
SPP offer closes	24 April 2014
Issue of shares under the SPP	1 May 2014
Expected date for commencement of trading of SPP shares	2 May 2014

For further information contact:

Richard Carreon, ImpediMed CEO Morten Vigeland, ImpediMed CFO T: +1 (760) 585-2100

About ImpediMed

ImpediMed Limited is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed’s primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed has the first medical device with an FDA clearance in the United States to aid health care professionals clinically assess secondary unilateral lymphoedema of the arm and leg in women and the leg in men.

For more information, visit www.impedimed.com.au